NASDAQ:ADGI Adagio Therapeutics (ADGI) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free ADGI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$3.40▼$4.7852-Week Range N/AVolume22,357 shsAverage Volume2.27 million shsMarket Capitalization$504.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Adagio Therapeutics alerts: Email Address Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. About Adagio Therapeutics Stock (NASDAQ:ADGI)Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.Read More Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. ADGI Stock News HeadlinesNovember 9, 2023 | msn.comAdagio Therapeutics GAAP EPS of -$0.36 beats by $0.15October 10, 2023 | nytimes.comOur Favorite Advent CalendarsAugust 11, 2023 | msn.comAdagio Therapeutics GAAP EPS of -$0.46 misses by $0.11April 3, 2023 | benzinga.comDEADLINE TODAY: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the FirmMarch 30, 2023 | markets.businessinsider.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the FirmMarch 3, 2023 | benzinga.comFILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Invivyd, Inc. – IVVD, ADGIFebruary 9, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGIJanuary 25, 2023 | finance.yahoo.comForm 8.3 - Horizon Therapeutics PlcDecember 19, 2022 | benzinga.comInvivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA WorkshopOctober 17, 2022 | bizjournals.comAdagio Therapeutics, now Invivyd, retools its strategy after losing two executivesSeptember 15, 2022 | finanznachrichten.deAdagio Therapeutics, Inc.: Adagio Therapeutics Announces Corporate Name Change to InvivydSeptember 12, 2022 | tmcnet.comInvivyd Announces Multiple Next Generation COVID-19 AntibodySeptember 12, 2022 | finance.yahoo.comInvivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron VariantsAugust 22, 2022 | 247wallst.comHedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%August 17, 2022 | seekingalpha.comAdagio Therapeutics GAAP EPS of -$0.47August 15, 2022 | finance.yahoo.comAdagio Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsJuly 6, 2022 | finance.yahoo.comIs Adagio Therapeutics (NASDAQ:ADGI) In A Good Position To Invest In Growth?July 5, 2022 | nasdaq.comAdagio Elevates Interim Chief Executive David Hering To Permanent CEOJuly 5, 2022 | finance.yahoo.comMithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy CampaignJuly 5, 2022 | finance.yahoo.comAdagio Announces David Hering Named Permanent Chief Executive Officer and DirectorJuly 2, 2022 | benzinga.com(ADGI) News: Did You Lose Money on Your Adagio Therapeutics Investment? Stock Price has Plummeted Since IPO - Contact Johnson FistelMay 13, 2022 | investing.comAdagio Therapeutics Reports Q1 Net Loss of $100.7M, Cash Position of $532.2MMay 13, 2022 | finance.yahoo.comAdagio Therapeutics Reports First Quarter 2022 Financial ResultsApril 14, 2022 | seekingalpha.comAdagio stock falls after pausing filing plans for COVID therapy with FDAApril 14, 2022 | finance.yahoo.comAdagio Therapeutics Provides Update on Timing of Adintrevimab EUA RequestSee More Headlines Receive ADGI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADGI CUSIPN/A CIK1832038 Webadagiotx.com Phone603-252-2274FaxN/AEmployees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.14% Return on Assets-50.28% Debt Debt-to-Equity RatioN/A Current Ratio7.09 Quick Ratio7.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.02 per share Price / BookN/AMiscellaneous Outstanding Shares108,831,000Free FloatN/AMarket Cap$504.98 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David Hering M.B.A. (Age 46)CEO & Director Comp: $453.76kMs. Jill Andersen J.D. (Age 49)Chief Legal Officer & Corp. Sec. Comp: $580.12kMs. Laura Walker Ph.D. (Age 37)Co-Founder & Chief Scientific Officer Ms. Jane Pritchett V. Henderson (Age 56)CFO, Chief Bus. Officer & Treasurer Dr. Rebecca Dabora Ph.D. (Age 62)Chief Technology & Manufacturing Officer Dr. Elham Hershberger Pharm.D. (Age 54)Chief Devel. Officer Mr. Eric W. Kimble M.B.A. (Age 54)Chief Commercial Officer Mr. Ed CampanaroSr. VP of Clinical OperationsMore ExecutivesKey CompetitorsImmunocoreNASDAQ:IMCRFusion PharmaceuticalsNASDAQ:FUSNNeumora TherapeuticsNASDAQ:NMRASana BiotechnologyNASDAQ:SANAVir BiotechnologyNASDAQ:VIRView All Competitors ADGI Stock Analysis - Frequently Asked Questions How were Adagio Therapeutics' earnings last quarter? Adagio Therapeutics, Inc. (NASDAQ:ADGI) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.24. When did Adagio Therapeutics IPO? Adagio Therapeutics (ADGI) raised $301 million in an initial public offering (IPO) on Friday, August 6th 2021. The company issued 17,700,000 shares at $16.00-$18.00 per share. This page (NASDAQ:ADGI) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.